Although the use of GnRH agonists to trigger ovulation has been shown to greatly reduce the risk of OHSS with no negative impact on oocyte quality or quantity [73], the risk of OHSS remains a concern for some patients. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.